ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
05 févr. 2024 09h00 HE
|
ProLynx Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023
12 avr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
27 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
CMMB Launches Breast and Cervical Cancer Project in Kitui County
11 janv. 2023 01h00 HE
|
Catholic Medical Mission Board
NAIROBI, Kenya, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) announced today that they have launched a cancer care project in Kitui South and Kitui Central sub-counties to...
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
19 oct. 2022 09h00 HE
|
Qualigen Therapeutics, Inc.
Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
06 oct. 2022 08h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers...
The Cancer Support Community Applauds the Appointment of Dr. Monica Bertagnolli to Director of the National Cancer Institute
10 août 2022 13h16 HE
|
Cancer Support Community
WASHINGTON, D.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC) enthusiastically supports President Biden’s selection of Monica Bertagnolli, MD to the position of director of...
Symple Surgical Awarded SBIR Phase I Grant for Novel Radiometry‐Guided Ablation Catheter to Reliably Treat Barrett's Esophagus
01 févr. 2022 09h00 HE
|
Symple Surgical
FLAGSTAFF, Ariz., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Symple Surgical Inc. (SSI) announced today that it has received a Small Business Innovation Research (SBIR) Phase I grant award totaling...
National Cancer Institute (NCI) Extends Long-Standing Partnership with Inspirata
29 sept. 2020 10h26 HE
|
Inspirata, Inc.
Tampa, Florida, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Inspirata announced today the renewal of its long-standing partnership with the National Cancer Institute (NCI). Building on almost two decades of...
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
30 avr. 2020 10h30 HE
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, April 30, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that investigators at the National Cancer Institute (NCI) and National Institute of...